APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1 BRCA2 or PALB2 Mutation

Brief description of study

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.


Clinical Study Identifier: s21-00636
ClinicalTrials.gov Identifier: NCT04858334
Principal Investigator: Paul E. Oberstein.
Other Investigators: Alexander A Hindenburg, Gary B Deutsch, Daniel J Becker, Kelly C O'Sullivan, Tiffany S Wang, Marta Wioleta Wronska, Lourdes Gaddi, Jennifer Chuy, Kristen Spencer, Monica Rivera, Shushma Upadhayay, Keriann M Scavone, Zefie Kanos, Nina Beri, Emmanuel Andres Pelayo, Anastasiya Apanasyuk, Ilana Zacharia, Rafael Winograd, Shun Yu, Michael Shusterman.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.